ALX Oncology
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 72
- Market Cap
- $131.1M
- Website
- http://www.alxoncology.com
- Introduction
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
- Conditions
- Bladder CancerUrothelial Carcinoma
- Interventions
- Drug: Enfortumab Vedotin
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05524545
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Massachusett's General, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
- Conditions
- Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05002127
- Locations
- 🇺🇸
The Oncology Institute of Hope & Innovation, Anaheim, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- Conditions
- Acute Myeloid LeukemiaAML, Adult
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04755244
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT04675333
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Oregon Health & Science University/ Knight Cancer Institute, Portland, Oregon, United States
Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT04675294
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Rutgers Cancer Institute of New Jersey, Newark, New Jersey, United States
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
- Conditions
- Higher Risk Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04417517
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸IU Simon Cancer Center, Indianapolis, Indiana, United States
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
- Conditions
- Metastatic CancerNonHodgkin LymphomaAdvanced CancerSolid Tumor
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT03013218
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of